Post-Marketing Studies Document Extra VTE Risk for Baricitinib
LONDON — Baricitinib (Olumiant) failed to show noninferiority to tumor necrosis factor (TNF) inhibitors for venous thromboembolism (VTE) risk in FDA-required postmarketing studies, a researcher reported here. In two large…
